GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (MEX:ALT1) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Altimmune (MEX:ALT1) Future 3-5Y EPS without NRI Growth Rate : N/A (As of May. 19, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Altimmune Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Altimmune's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Altimmune's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Altimmune's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Altimmune's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altimmune's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Altimmune's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Altimmune  (MEX:ALT1) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Altimmune Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Altimmune's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Altimmune Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (MEX:ALT1) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
RAPP TECX ZVRA ERAS VSTM SANA ABSI ORKA CELC ORIC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
ALT:USA 0A4C:UK 3G0:Germany 3G0:Germany
Address
910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Website
https://www.altimmune.com
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune Headlines

No Headlines